Advanced search
Publication Cover
Expert Review of Dermatology Volume 8, 2013 - Issue 2
Journal homepage
7
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

The prognostic significance of BRAF mutation status in stage IIIB–C melanoma

MG Niebling Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
,
KP Wevers Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
&
HJ Hoekstra Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. [email protected]
Pages 127-129 | Published online: 10 Jan 2014

References

  • Moreau S, Saiag P, Aegerter P et al. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann. Surg. Oncol. 19(13), 4314–4321 (2012).
  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893–2917 (2010).
  • Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 6(8), 608–621 (2005).
  • Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199–6206 (2009).
  • Balch CM, Gershenwald JE, Soong SJ et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28(14), 2452–2459 (2010).
  • Balch CM, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 224(3), 255–263; discussion 263 (1996).
  • Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351(9105), 793–796 (1998).
  • Hughes TM, A’Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br. J. Surg. 87(7), 892–901 (2000).
  • van Akkooi AC, Bouwhuis MG, van Geel AN et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur. J. Surg. Oncol. 33(1), 102–108 (2007).
  • Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet 374(9687), 362–365 (2009).
  • Burmeister BH, Henderson MA, Ainslie J et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 13(6), 589–597 (2012).
  • Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 75(Suppl. 2), 726–734 (1995).
  • Lens MB, Dawes M. Interferon α therapy for malignant melanoma: a systematic review of randomized controlled trials. J. Clin. Oncol. 20(7), 1818–1825 (2002).
  • Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).
  • Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  • Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809–819 (2010).
  • Kruijff S, Hoekstra HJ. The current status of S-100B as a biomarker in melanoma. Eur. J. Surg. Oncol. 38(4), 281–285 (2012).
  • Wevers KP, Kruijff S, Speijers MJ, Bastiaannet E, Muller Kobold AC, Hoekstra HJ. S-100B: a stronger prognostic biomarker than LDH in stage IIIB–C melanoma patients. Ann. Surg. Oncol. (2013) (In Press).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.